Cibus, Inc. (NASDAQ:CBUS) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET

Company Participants

Wade King - Chief Financial Officer
Rory Riggs - Co-Founder, Chairman and CEO
Peter Beetham - Co-Founder, President and COO

Conference Call Participants

Nick Anderson - ROTH Capital
Matthew Venezia - Alliance Global Partners
Austin Moeller - Canaccord
Sameer Joshi - H.C. Wainwright
Steve Byrne - Bank of America

Operator

I’d like to turn the conference over to Wade King, Chief Financial Officer. Sir, please go ahead.

Wade King

Thank you and good afternoon. This is Wade King, the Chief Financial Officer of Cibus. I would like to thank you for taking time to join us for Cibus’ Second Quarter Of 2024 Financial Results and Corporate Update Conference Call and Webcast. Presenting with me today is Rory Riggs, our Co-Founder, Chief Executive Officer and Chairman; and Peter Beetham, Co-Founder, President and Chief Operating Officer.

Before we begin the call, I’d like to remind everyone that statements made on the call and webcast, including those regarding future financial results and future operational goals and industry prospects, are forward-looking and may be subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the call. Please refer to Cibus’ SEC filings for a list of associated risks.

This conference call is being webcast. The webcast link, along with our press release and corporate presentation, are available on the Investor Relations section of cibus.com to assist in your analysis of the business.

With that, I would now like to turn the call over to Mr. Riggs. Go ahead, Rory.

Rory Riggs

Thanks, Wade. I would like to begin this call with a high-level update on our business activities in this quarter and in this year. Following my remarks, Peter will walk you through our recent developments in more detail. In addition, he will review the value proposition for all of our developed trades and discuss how we’re doing on our expected 2024 milestones to help you understand why we are so excited with our progress. Wade will then finish with a discussion of the financials.

I’d like to start by reviewing the business we created last year when we merged Cibus and Calyxt. When we merged, we were the two leading gene-editing companies in terms of owning the foundational patents and technology for gene-editing in agriculture. These cover exclusive proprietary use of the foundational intellectual property in the agricultural gene-editing industry, including our GRON Editing Technology Platform, the exclusive use of TALENs in agriculture, and in certain geographies, the exclusive use of CRISPR Technology in agriculture.